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ABSTRACT 
 
In silico models are essential for the development of integrated alternative methods to identify 
organ level toxicity and lead towards the replacement of animal testing. These models include 
(quantitative) structure-activity relationships ((Q)SARs) and, importantly, the identification of 
structural alerts associated with defined toxicological endpoints. Structural alerts are able both 
to predict toxicity directly and assist in the formation of categories to facilitate read-across. 
They are particularly important to decipher the myriad mechanisms of action that result in 
organ level toxicity. The aim of this study was to develop novel structural alerts for nuclear 
receptor (NR) ligands that are associated with inducing hepatic steatosis and to show the vast 
amount of current data that are available. Current knowledge on NR agonists was extended 
with data from the ChEMBL database (12,713 chemicals in total) of bioactive molecules and 
from studying NR ligand-binding interactions within the protein data base (PBD, 624 human 
NR structure files). A computational structural alerts based workflow was developed using 
KNIME from these data using molecular fragments and other relevant chemical features. In 
total 214 structural features were recorded computationally as SMARTS strings and, therefore, 
they can be used for grouping and screening during drug development and hazard assessment 
and provide knowledge to anchor adverse outcome pathways (AOPs) via there molecular 
initiating effects (MIE). 
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INTRODUCTION 
Nuclear receptors (NR) belong to a large superfamily of ligand-inducible transcription factors 
that, upon activation, mediate the expression of their target genes.1 The ligands associated with 
NR activation are usually lipophilic, small in size and include the following chemical classes: 
endogenous steroids, oxysterols, thyroid hormones as well as various lipids and retinoids.2,3 
NRs are essential for the regulation of specific target genes that are involved in development, 
metabolism, reproduction and other vital physiological processes. Upon ligand-induced 
activation, NRs elicit a rapid cellular adaptation to environmental changes via the induction of 
the required genes and pathways.4  
Due to their involvement in many essential processes within the body, the search for novel 
ligands for nuclear receptor(s) (NR(s)) has intensified in order to identify possible preventative 
/ therapeutic treatments for a wide range of diseases including diabetes, cancer, cardiovascular 
diseases, atherosclerosis, neurodegenerative diseases and obesity.3,4 For example, the 
oestrogen receptor (ER) antagonist tamoxifen is used for the treatment of ER positive breast 
cancer.5-7 As NR ligands are widely used it is imperative their safety is considered, as there are 
reports of NR ligands leading to drug induced liver injury (DILI), such as liver steatosis, due 
to the bio-activation of drugs (or metabolites) and / or the induction of hepatotoxic pathways. 
8-11
  
Traditional approaches to determine safety have required the use of animal tests. However, the 
promotion of what is termed “21st Century Toxicology” has led to the move from traditional 
animal testing safety assessment methods to the use of integrated alternative strategies which 
utilise toxicokinetics, computational models and in vitro testing.10,12-14, 15 The shift in the mind 
set occurring within toxicology has given rise to the concept of the Adverse Outcome Pathway 
(AOP) framework.13-14, 16-18 An AOP describes the causal linkage between a molecular 
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initiating event (MIE) and an adverse outcome at individual or population level.12,18 The AOP 
developed within the current AOP Wiki knowledge base (AOP-KB) for hepatic steatosis 
defines liver toxicity as the adverse effect and nuclear receptor binding being the MIE, thus 
this knowledge provides the starting point for computational methods.14,18,19  
Computational methods include the use of (quantitative) structure-activity relationships 
((Q)SARs) as well as other approaches including biokinetic models. QSARs require the use of 
mathematical models in order to predict biological activity of chemicals from their structure or 
physico-chemical properties. An SAR is a qualitative link between a certain molecular 
substructure to a specific biological activity.20 Structural alert(s) (SA(s)) derived from SARs 
can aid in the formation of categories with similar chemicals that are associated to share the 
same SAR. The assessment of these category members can, in turn, allow for the better 
definition of the domain of the SA.20,21 SA are common structural fragments that are associated 
with a specific toxicity which very often have mechanistic rational to support these links – with 
reference to an AOP this is in terms of the MIE. 20-22 SAs are already used to screen potential 
lead chemicals for idiosyncratic toxicity within industry settings.24 Thus, through knowledge 
of the AOP, they can form the first step in understanding the links from a specific chemical to 
its possible mechanistic pathways and those organs that may be affected.20 For the AOP concept 
to be applied, particularly to support category formation and read-across, an SA associated with 
a MIE for a particular adverse pathway must be elucidated and described. 
The use of new (toxicological and informatics) approaches can help to aide in the formation of 
SAs; for instance, applying freely available software and utilising the growing number of open 
access databases of toxicological information.25 For this study, the new methods approaches 
used included the ChEMBL database of bioactive molecules (with >1.5 million compounds 
and 9,000 biological targets), KoNstanz Inforamtion MinEr (KNIME) software (allows the 
analysis/ mining of data and can be used to build predictive models) and the protein data bank 
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(PBD), (a database of > 100,000 crystallographic structures of proteins e.g. receptors which 
can be analysed alongside software such as PyMOL and Marvin Beans, a ChemAxon suite of 
programmes that allow the visualisation and drawing of chemicals, all of which are freely 
available).26-30 
Mellor et al. (2015) reviewed the NRs linked to liver injury, identifying ten NRs that can cause 
the onset of hepatic steatosis, these are summarised in Table 1.18 Each of these NRs is 
associated with a definable mechanism of action and / or toxicity pathway that could form the 
basis of an AOP. A MIE is definable for each NR, therefore with analysis of suitable data for 
NR binding, this raises the possibility of defining a suite of SA which could form the basis of 
toxicity prediction or grouping. Thus, the aim of this study was to develop a set of SAs for the 
NRs associated with hepatic steatosis listed in Table 1. This was achieved with reference to the 
MIEs for the NR and utilised the ChEMBL database as a source of information. A workflow 
was created to collate knowledge that can predict binding to the NR listed in Table 1.26 The 
workflow was developed in a two-step process. The first step involved identifying the physico-
chemical properties that define the chemical space/ domain of agonists of the NR through the 
calculation of descriptors from studying the chemical structure. The second step involved the 
identification of structural features associated with NR binding which were then coded into 
SMARTS strings so they could be implemented in the workflow. The identification of 
structural features was performed by studying the ligand-binding interactions of the agonists 
to their respective NR using the PDB files viewed in PyMol and by studying the literature 
associated with these files (referenced within PDB).28,29,31 The workflow can be used for hazard 
assessment, screening of potential ligands for chemical leads or grouping. The workflow is 
freely available to use and download from COSMOS Space 
(http://knimewebportal.cosmostox.eu) To view a web tutorial describing the use of the workflow 
please use the following link (https://www.youtube.com/watch?v=ggkU6lZfDfY). 
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TABLE 1 HERE 
 
METHODS 
Identifying chemical structures with relevant NR binding data from ChEMBL  
The 10 NR listed in Table 1 were searched for within the online ChEMBL database (Version19) 
using their names and standard nomenclature identifiers in order to find agonists.26 To identify 
agonists, the names and / or nomenclature of the NRs, as reported in Table 1, were entered into 
the search bar within the online ChEMBL website with Homo sapiens selected as the species 
of interest. Data retrieved were downloaded to comma-separated values (.csv) files and later 
saved in an Excel spreadsheet. Those data with pChEMBL values were selected and all other 
chemicals without these values were removed. The pChEMBL value is an approach to 
standardise different types of activity values.32 In addition, the following information was 
obtained from ChEMBL: the chemical name, molecular formula, SMILES string of each 
agonist, the assay type (e.g. receptor activation), activity value (reported as Ki, Kd, AC50, IC50, 
and EC50) and other relevant information regarding the assay. Only agonistic Ki, Kd, AC50 
or EC50 values were utilised to remove data relating to inhibition of receptors (e.g. those with 
IC50 values / Ki values) and to ensure receptor activation data were considered. Chemicals 
were then ordered by pChEMBL value (highest to lowest) and those with a pChEMBL of <5 
removed. The pChEMBL of > 5 was used as the threshold for activity as when studying the 
ChEMBL data this was the point at which most of chemicals were considered active and has 
been utilised previously.33,34 Duplicate chemicals were removed at this point. Agonists with 
pChEMBL values above the threshold value were studied using the Marvin Bean (version 1.6) 
chemical visualisation software in order to find common structural features associated with NR 
activation; these features were recorded as SMARTS strings.30,31  
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Analysis of ligand-binding information from the Protein Data Bank (PDB) 
The PDB was investigated in conjunction with the list of agonists and associated data obtained 
from ChEMBL to further study the ligand-binding of agonists to their respective NR. The NR 
names /nomenclature (Table 1) were searched for on the PDB website and human NR files 
containing information about agonistic binding to human NR structures were selected. The 
selected files were viewed to study their ligand-protein interactions using PyMOL (version 1.3) 
and the linked publications provided within the PDB were read to find the key amino acid 
residues on the NR binding site that have been shown to interact with specific functional groups 
on the ligand. The functional groups on the agonists needed for these essential binding 
interactions with the NR binding site such as hydroxyl moiety group were then drawn as 
SMILES strings and added to form the rules of the workflow. 28, 29, 31  
 
Calculation of Molecular Descriptors 
Molecular properties and other descriptors for the agonists were calculated using the CDK node 
in KNIME (version 3.2).27 SMILES strings for the ligands were retrieved from ChEMBL and 
then cleaned (removal of salts, inorganics and mixtures). The SMILES were entered into the 
CDK node and all available descriptors (33 available within CDK node) were calculated. 
Descriptors were identified that described features relevant to ligand-protein interactions and 
gave a specific range of values for each NR. In total eight descriptors were used: molecular 
weight (MW, describing molecular size), the calculated logarithm of the octanol-water partition 
coefficient (xlogP, lipophilicity), vertex adjacency matrix (VAIM, molecular size and 
complexity), number of hydrogen bond acceptors / donors (HBA/ HBD, binding interactions), 
eccentric connectivity index (ECI, structural complexity), topical polar surface area (TPSA, 
relative polarity) and the number of rotatable bonds (RB, molecular flexibility and entropy). 
Development of Workflows 
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KNIME (version 3.2) was used to build a structural feature-based workflow to screen for 
ligands predicted to bind to NR that are associated with the onset of hepatic steatosis (Table 1). 
The workflows executed rules based on physico-chemical properties and structural features 
established through studying relevant pChEMBL values and the structural information within 
PDB. The main KNIME workflow is an amalgamation of eight smaller workflows for each NR 
making screening chemicals fast and easy for users. Each of these individual workflows is 
made up of two steps. The first calculates physico-chemical properties of the chemicals being 
screened to identify if the chemicals are in the chemical space defined previously (descriptor 
ranges applied). The second step runs the chemicals being screened against the structural 
features found to be essential for receptor binding that have been developed for each NR. In 
summary the workflow firstly identifies if a compound is in the chemical space associated with 
being an agonistic binder, then whether it has the structural features required for binding, which 
is an informed method of grouping for receptor mediated effects. 
The workflow developed allows users to enter one chemical to be screened for NR binding 
(either via a .csv file containing the SMILES string for the chemical or by drawing the chemical 
structure using the drawing tool available) or via a batch  process (using a .csv file containing 
the SMILES for all the chemicals being screened). The output of the workflow is a table of all 
the chemicals that were identified as binders to one or more of the NR listed in Table 1 (note: 
RAR and RXR are combined and CAR is not present within the workflow, see the CAR section 
in the Results), the NR that they are predicted to bind to are listed. If a batch is run and no 
chemicals are identified as possible binders, a message will appear to let the user know that 
their chemicals are deemed not to be a binder to the NRs listed. 
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RESULTS 
Data and information obtained from ChEMBL and PDB 
Data and other information about ligand binding were extracted from ChEMBL and the PDB 
for the ten NR listed in Table 1. The number of agonists obtained from ChEMBL, those deemed 
to be active, the range of pChEMBL values found for each NR and the number of human PDB 
files (which contain crystallographic representations of the NRs binding with agonists) found 
associated with each NR is summarised in Table 2. 
 
TABLE 2 HERE 
 
Descriptor ranges applied 
Descriptors were calculated within KNIME using the CDK node. Descriptors were calculated 
for all agonists collected from ChEMBL that were identified as active (pChEMBL > 5). Eight 
descriptors were chosen in total and these were selected as they gave information relevant for 
ligand binding/ ligand shape and so define the chemical space for the properties needed to bind 
to the NR of interest. A summary of the ranges used for the molecular descriptors and applied 
for each NR within the workflow is presented Table 3 below. 
 
TABLE 3 HERE 
 
Ligand-protein binding information and building of SA 
From studying the ligand binding interactions found within the crystallographic PDB files of 
human NR to known agonists, key structural features that were shown to be essential were 
identified. These structural features were classed as essential as they occurred in many of the 
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PDB files showing agonistic binding for the NR, also the papers associated with each PDB file 
made reference to these important structural features, therefore this knowledge was built upon 
and added to using knowledge obtained from ChEMBL (chemical structure obtained and 
activity values for known agonists of each NR). The structural features that were developed for 
the workflow are summarised below for each NR studied. N.B the tables showing structural 
features found for each NR are only shown for the AHR receptor – all others are found within 
the supporting information. 
AHR 
The PDB files associated with agonistic binding to the human AHR receptor were studied along 
with the shape of the agonists obtained from ChEMBL. From these the ligand-binding patterns 
and those chemical features present in all known AHR agonists were identified. It was found 
that ligands must form interactions (usually via hydrogen bonds) with the key residues Met328, 
Tyr353 and Phe367 found within the AHR binding pocket in order to activate the AHR NR.35 
These structural features were then coded into SMARTS strings.31 The AHR workflow was 
split into two parts, firstly the chemical must contain at least one of the backbone ring structures 
as reported in Table 4 (showing the SMARTS strings and visual representations) as these were 
observed as being essential to fitting into the binding pocket. Secondly the chemical must 
contain either one of the oxygen functional groups seen in Table 5 or substitutes for oxygen 
(nitrogen/chlorine groups) reported in Table 6. The oxygen/nitrogen functional groups were 
observed to be essential to form hydrogen bonds between the ligand and the ligand binding 
pocket of the AHR. 
 
TABLE 4 HERE 
TABLE 5 HERE  
TABLE 6 HERE  
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CAR 
When searching for data associated with the CAR NR within the ChEMBL database, only 40 
chemical structures could be found. Furthermore, no pChEBML values were assigned to these 
chemicals. As the quantity and quality of the data available for CAR were limited, this NR was 
excluded from model development. This should be noted as a subject for further investigation 
in future to develop structural alerts for this NR and also for the development of AOPs.  
ER 
The binding of ER agonists was observed (within the PDB files containing crystallographic 
representation of agonists binding to the human ER). It was found that a ligand must interact 
with the key residues Arg346, Glu 305 and H13475 within the ER binding domain in order for 
ER activation.36 The bonds formed in order for this interaction to occur involved hydrophobic 
van der Waals interactions within the lipophilic pocket. The structural features of ligands that 
occurred in the PDB files were coded into SMARTS patterns. The binding of ER agonists was 
shown to be similar to other steroid hormone NRs with the exception that binding was found 
to be different for ER agonists with a higher molecular weight. Therefore the ER workflow 
first splits the chemicals being screened based on MW within the range (700< MW < 2250), 
the MW range was selected based on the MW of the known binders within ChEMBL. Those 
chemicals with a MW within this range were checked against the steroid structure check 
(Supplementary data - Table S1). Those chemicals with a MW less than 700 pass through the 
usual descriptor checks and then proceed to the structural feature screening. Similar to the AHR 
rules, the chemical must contain at least one of the essential scaffold ring SA (Supplementary 
data - Table S2) and one of the oxygen functional groups (Supplementary data - Table S3) or 
nitrogen functional group (Supplementary data - Table S4). The oxygen and nitrogen functional 
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groups were found to form essential hydrogen bonds between the ligands and the ligand 
binding pocket. 
FXR 
Structural features implemented for FXR screening are expressed in Supplementary data Table 
S5 and S6. The residuals of arginine and histidine, sometimes incorporating water molecules, 
form hydrogen bonds with carboxylic groups (3BEJ). The threonine, asparagine and glutamic 
acid residues may form further hydrogen bonds, in particular to oxygens (4II6, 3BEJ). Sub-
structural patterns in FXR ligands are mainly defined by oxygens, and to a lesser extent, 
nitrogens, sulphurs and halogens, and the manner in which they are attached to aromatic and 
aliphatic ring structures. Many ligands do not have significant structural resemblance to the 
endogenous ligands, such as chenodeoxycholic acid.37 
GR 
The conclusions from the PDB files and literature searches revealed that ligands that bind with 
high affinity to GR contain a ketone group (or other similar substitute group) which forms 
hydrogen bonds between the ARG-611 and Gln-570 amino acid residues on the ligand binding 
pocket of the GR.38 The hydrogen atom from the 17b-hydroxyl group has a partial positive 
charge which allows it to interact and form bonds with highly electronegative atoms that are 
bound to an amino acid residue.  These essential features were coded into SMARTS strings. 
The first step within the GR workflow splits the chemicals depending on MW. Chemicals that 
had MW within this range (610 < MW < 1200) went through one check to look for the ring 
structure as described in supplementary data, Table S7. Those chemicals with a MW less than 
610 are screened against the descriptor ranges (Table 3) and to identify essential structural 
features. The chemical must contain a backbone ring structure (Supplementary data - Table S8) 
and must also contain either an oxygen group (Supplementary data - Table S9) or a nitrogen 
group (Supplementary data – Table S10). The binding observed for GR actives was similar to 
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that observed for other steroid based NR. They have specific ring structures with many oxygen 
/ nitrogen functional groups that help to form strong hydrogen bonds between the ligand and 
ligand binding pocket.  
LXR 
LXR actives were studied and the sub-structural features were coded into SMARTS strings 
(Supplementary data - Tables S11 and S12). A potential ligand contains a ring backbone, which 
may have interactions with phenylalanine, tryptophan and histidine residues, in particular π-π 
stacking. Furthermore, the compound must also contain functional groups, in particular 
terminal oxygens, interacting with arginine or threonine residues and the secondary amine of a 
leucine (PDB: 3LOE, 4NQA, 4DK7), as can be seen in Figure 1 showing hydrogen bonding 
between the ARG319 and LEU330 residues of the LXR binding pocket to the oxygen groups 
of the ligand. 
 
FIGURE 1 HERE 
 
PPAR 
PPAR actives were studied and the sub-structural features were coded into SMARTS strings. 
The chemical must not contain a steroid backbone (Supplementary data - Table S13) but must 
contain one of the specific “diaromatic” scaffold and one of the specific functional groups in 
order to be an active. Additional alerts describe fatty acid- and retinoid-like compounds, which 
may have moderate PPAR affinity (Supplementary data - Tables S14, S15 and S16).  
PXR 
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It was found that ligands of the PXR must form interactions (usually hydrogen bonds) with the 
key residues Ser 208, Ser247, GLn285, His407 and Arg410 within the PXR binding pocket in 
order for PXR activation to occur.39 The sub-structural features of PXR actives studied were 
coded into SMARTS strings. Similar to the other steroidal NR, the chemical must contain at 
least one of the essential scaffold ring SA (Supplementary data - Table S17) and one of the 
oxygen functional groups (Supplementary data - Table S18) or nitrogen functional group 
(Supplementary data - Table S19). The oxygen and nitrogen functional groups were found to 
form hydrogen bonds between the ligands and the ligand binding pocket. 
RAR/RXR 
After observing the RAR and RXR receptors separately it was noted that their actives had very 
similar binding patterns and it was decided to combine them into one workflow. Generally 
RAR/RXR ligands are lipophilic, but there are a few compounds which are active without being 
lipophilic (XLogP < 2.2), e.g. n-phosphono-L-phenylalanyl-L alanylglycinamide with an 
XLogP of -2.4. As these compounds have peptide-like bonds, XLogP exception rules were 
created (Supplementary data - Table S21). To narrow down the compounds passing through 
this alert, such as inactive amino sugars, a further filter (Supplementary data - Table S22) was 
used. As shown in Figure 2, there are certain groups (in particular double bond oxygens), 
binding to arginine and serine residues, e.g. the hydrogen bond between ARG278 or SER289 
and an oxygen of a ligand’s carboxylic group within the RAR domain. The responsible 
structural features are described in the alerts (Supplementary data - Table S23). Furthermore 
RAR/RXR ligands contain at least one ring structure, which could be aromatic or aliphatic, e.g. 
cyclohexene of retinoic acid, as expressed in the SA (Supplementary data - Table S24). 25, 40 
FIGURE 2 HERE 
Testing the screening workflow 
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The ChEMBL chemicals deemed to be active via their pChEMBL value were used to test if all 
of the chemicals that are known agonists for the NR of interest (Table 1) are identified by the 
screening workflow. The results demonstrated that all of the chemicals that have been 
identified as binders within ChEMBL were successfully predicted as binders to their associated 
NR showing that the workflow was accurate at identifying chemical’s as being binders . 
 
DISCUSSION 
21st Century Toxicology relies heavily on the development of alternative testing methods 
(computational, biokinetics, in vitro) as opposed to the traditional extensive animal methods 
used previously. Alternative approaches now favour the inclusion of computational models, 
however, traditional in silico models (QSARS/SARs) have struggled in the past to deal with 
organ level toxicity. Despite this, recently there has been some improvement through the use 
of SA, especially focussed on MIEs.21-23 In general, SA are well developed for MIEs depending 
on the reactivity of a xenobiotic with a biological macromolecules, for instance the formation 
of covalent bond as demonstrated by the many profilers (e.g. for protein or DNA binding) 
implemented in the OECD QSAR Toolbox. It remains much more difficult to develop profilers 
for receptor mediated toxicity, with the current state of the art being MIE-derived 2D 
descriptors.21-23,41,42Whilst these issues are recognised, encouraging recent studies have shown 
that it is possible that useful information and models, including profilers, can be developed for 
receptor mediated toxicity.43,44  
 
Whilst it is becoming common place to code 2D interactions e.g. protein / DNA binding as 
molecular fragments, the next challenge lies with the grouping of receptor mediated effects. 
Ultimately the modelling of most receptor-ligand interactions must address the use of 
molecular modelling and other types of molecular design software, and a framework for 
undertaking this task has been presented recently.43 Despite the simplicity of a 2D approach, 
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progress can be made rapidly,23 and such profilers are amenable to use in e.g. the OECD QSAR 
Toolbox.45 In this study the issue of the capture of information relating to MIE has been 
addressed, in part, by the use of structural alerts based workflows. SA can be used both as a 
direct predictor of toxicity and also for grouping chemicals for read across. Through the 
development of AOPs, SA can be used collectively if they have the same MIE, our 
understanding of this MIE can then provide a linkage to mechanistic pathways and the adverse 
effects induced via these pathways. AOPs are now integral to risk assessment, therefore, AOP 
development is important and the role SA play in their implementation is essential. 
There are many (Q)SAR models available for the prediction of NR mediated effects.46 
Therefore, the purpose of this study was not to repeat previously undertaken work but rather to 
build on existing knowledge to create a new set of SA/ structural features that can be 
implemented in an in silico workflow. This investigation has focused on NR previously linked 
to the onset of hepatic steatosis.18 Within this study the use of new generation resources (PBD, 
pChEMBL, KNIME, PyMOL, Marvin Beans) has been a key element. This demonstrated how 
existing data may be used in future studies to create knowledge regarding toxicological 
interactions. A total of 12,713 chemicals were identified in ChEMBL that were linked to NR 
and could be used in this study (with a pChEMBL >5). In addition 624 human PDB files 
showed binding information of ligands to the NR of interest for this study. These figures show 
the vast amount of current data that are available and, when linked to AOPs, have the potential 
to provide a goldmine of information. 
Generally all workflows in this study can be divided into two essential steps. The first step 
involves the screening for ligand-specific physico-chemical descriptors and the second step 
involves the use of sub-structural features. The sub-structural features produced for most of the 
NR workflows follow a similar pattern of scrutinising for key scaffolding structures (e.g. ring 
structures) and then further screening for essential functional groups. However, there are a few 
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exceptions such as for RXR and PPAR (which have some exclusion rules) and for GR, AR, 
ER and PXR (which have high MW filter to account for those ligands that were larger and had 
different receptor binding patterns compared the low MW ligands).  
Within the literature it remains unclear what role the different nuclear receptor subtypes play 
in terms of activation of the pathways associated with each NR.47 As the binding of ligands to 
the different receptor subtypes was observed to overlap, it was decided to combine the subtypes 
into one screening workflow. It would have been challenging to develop structural features for 
one specific receptor subtype as many ligands are able to bind to different subtypes albeit 
sometimes with different affinities although this would remain a long term goal. For example, 
the ER agonist raloxifene has PChEMBL value of 10.52 for the ERα and a PChEMBL value 
of 8.8 for the ERβ therefore, it can be seen that these molecules share similar MIE’s across two 
different NR. Also it cannot be determined if one ligand only binds to one receptor subtype due 
to the constraints of the data available in the ChEMBL database. Therefore a NR workflow, 
such as for ER, is a combined workflow incorporating all receptor subtypes, such as ERα and 
ERβ. It was noted that the ligands of some of the NR were similar, particularly those that are 
specific for retinoids (e.g. RAR and RXR ligands) and steroids (e.g. AR, ER and GR ligands). 
This means that ligands may have the ability to activate many NRs (to a certain extent). As 
predictions for promiscuous receptors can be difficult, the full set of predictions is given within 
the output file of the screening workflow.  
This generalistic approach has the advantage of rapidly identifying chemicals that have a 
similar structure to previously known NR binders and has been tailored specifically towards 
human NR binding. However, because this method focuses only on qualitative identification 
of alerts associated with the initial event in an AOP, it cannot be used as a standalone for hazard 
identification (identifying the potential for harm) or risk assessment (the likelihood of harm 
associated with specific patterns and levels of exposure). The ability to predict an AO will 
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depend upon the scientific confidence in the predictive models that link quantitation of 
upstream key events (e.g., the MIE) to downstream key events in the AOP and the ability to 
predict risk involves integrating knowledge of toxicokinetics, biological activity, dose response 
with predicted or modelled exposures.12, 48 Nevertheless, the workflow can be very useful in 
reducing, refining or replacing traditional animal toxicity testing. It can be used to develop 
categories of substances for use in read across to enable inference from measured human health 
and/or environmental properties/endpoints from reference substance(s) within the group to fill 
data gaps for substances that lack data for such properties / endpoints. In addition, the workflow 
can also be used for prioritisation to differentiate chemicals that may require further testing as 
part of an integrated testing strategy from those that do not show structural alerts for specific 
NR pathways.49 For example, the workflow could potentially be applied to initiatives such as 
the USEPA’s Endocrine Disruptor Screening Program as the initial step in setting priorities for 
further in vitro or in vivo screening for oestrogen, androgen or thyroid activities; substances 
that do not trigger SAs would be deprioritised.50  
 
CONCLUSIONS 
214 structural features were developed from MIEs associated with AOPs and combined with 
eight different descriptors to create a decision based workflow for each NR. The individual NR 
workflows have been amalgamated into one large screening workflow for all NRs investigated 
and with the focus being the NRs associated with the onset of hepatic steatosis. This study 
highlights that modern technologies (PDB, CheMBL, KNIME) provide new opportunities, due 
to their extensive data, to build alerts and use the information potentially contained with AOPs. 
This study is the first to produce a SA based workflow of this size for a receptor mediated 
toxicity, in this case linked to hepatic steatosis as the target organ adverse effect through the 
AOP. The workflow produced has addressed the problem of grouping chemicals that have 
hepatic steatosis as their endpoint, a previously difficult task.  
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Table 1: Nuclear receptors associated with hepatic steatosis and abbreviations as defined by Mellor et 
al 2015.17 
Nuclear receptor name Abbreviation Nomenclature Identification 
Aryl Hydrocarbon Receptor  AHR bHLHe76 
Constitutive Androstane Receptor  CAR NR1I3 
oEstrogen Receptor  ER NR3A1/2 
Farnesoid X Receptor  FXR NR1H4/5 
Glucocorticoid Receptor  GR NR3C1 
Liver X Receptor  LXR NR1H2/3 
Peroxisome Proliferator-Activated Receptor  PPAR NR1C1-3 
Pregnane X Receptor  PXR NR1I2 
Retinoic Acid Receptor  RAR NR1B1-3 
Retinoid X receptor RXR - 
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Table 2: Summary of the data and information obtained from ChEMBL and the PDB for the different 
NR agonists 
 
Nuclear 
receptor 
Number of agonists obtained from 
ChEMBL 
Range of 
pChembl values 
for chemicals 
Number of PDB files 
found that contain 
human NR 
structures Total with pChEMBL > 5 
AHR 219 170 4.0 - 9.35 20 
CAR - - - - 
ER 7528                   (4586α) (2942β) 
1489                   
(791α) (698β) 4.14 - 11.00 249 
FXR 799 602 4.21 - 8.7 23 
GR 2029 2021 4 - 10 62 
LXR 1536                   (749α) (787β) 
812                     
(368α) (444β) 4.09 – 9.00 16 
PPAR 
13358                 
(4034α) 
(3040β)(6284γ) 
5700                   
(1999α) 
(1196β)(2505γ) 
4.00 – 10.74 166 
PXR 463 135 4.00 – 9.15 68 
RAR 
2511                   
(848α) 
(878β)(785γ) 
855                     
(258α)             
(325β)(272γ) 
4.55 – 10.4 20 
RXR 
2380                   
(1845α) 
(263β)(272γ) 
950                     
(563α)             
(189β)(198γ) 
4.68 – 10.1 109 
Note: α, β and γ values given in parentheses are the number of chemicals found that are associated 
with binding to either the α, β or γ subunit of the NR 
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  Table 3: The descriptor ranges used for all NR and implemented within the workflow 
Physico-
chemical 
property 
Value 
AHR CAR ER FXR GR LXR PPAR PXR RAR/RXR 
VAIM 4.5-6.5 - 4 - 7.5 - 4 - 8.5 4.7 - 7 5 - 7 5 - 7 5 - 7 
HBD < 6 - < 10 - < 15 - - < 5 - 
MW 180 - 900 - 140 - 700 > 900 180 - 610 < 750 < 800 300 - 610 < 550 
HBA < 10 - < 15 - < 15 - - < 10 - 
XLogP < 8 - < -2 - < -1 < 2 - < 0 - 
ECI - - - 150  - 2400 - - - - - 
RB - - - 3- 11 - - - - 3 - 30 
TPSA - - - 15 - 200 - 5 - 150 1.2 - 20 - - 
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Table 4: SMARTS strings and chemical structure of backbone ring for AHR actives. 
 
 
 
 
 
 
SMARTS string Structual Feature
[#7,#6,#8,#16]1[#7,#6,#8,#16][#7,#6,#8,#16][#7,#6,#8,#16]([#7,#6,#8,#16]1)-c1ccccc1
[#6]~1~[#7,#6,#8]~[#7,#6,#8]~[#7,#6,#8]~[#6]~[#6]~1-c1ccccc1
[#8,#6,#7,#16]~1~[#8,#6,#7,#16]~[#8,#6,#7,#16]~[#6](~[#8,#6,#7,#16]~[#8,#6,#7,#16]~1)-[#7,#8,#6,#16]-c1ccccc1
[#8,#7,#6]~1~[#8,#7,#6]~[#8,#7,#6]~c2ccccc2~[#8,#7,#6]~1
O=[#6](-[#7]-c1ccccc1)-c1[#7,#6][#7,#6][#7,#6][#7,#6][#7,#6]1
[#7,#6,#8]~1~[#7,#6,#8]~[#7,#6,#8]~2~[#7,#6,#8]~[#7,#6,#8]~[#7,#6,#8]~[#7,#6,#8]~[#7,#6,#8]~2~[#7,#6,#8]~1
C(=C\c1ccccc1)\c1ccccc1
c1nc2ccccc2s1
[#6]-[#7]-c1ccccc1-[#9,#17]
[#6;A][#7]-c1ccc(-[#9,#17,#1])c(-[#9,#17,#1])c1
L
[O,N,C]
L
[O,N,C]
L
[O,N,C]
L
[O,N,C]
L[N,C,O]
L
[N,C,O]
L
[N,C,O]
L
[N,C,O]
L
[N,C,O]
L
[N,C,O]L
[N,C,O]
L
[N,C,O]L
[N,C,O]
N
S
H
3
C
NH
L[F,Cl]
C(A)
NH
L
[F,Cl,H]
L
[F,Cl,H]
L
[N,C,O,S]
L
[N,C,O,S]
L[N,C,O,S]
L
[N,C,O,S]
L [N,C,O,S]
L
[N,C,O]L
[N,C,O]
L
[N,C,O]
L
[O,C,N,S]
L
[O,C,N,S]
L
[O,C,N,S]
L
[O,C,N,S]
L
[O,C,N,S]
L [N,O,C,S]
O NH
(a)
L
[N,C]
L[N,C]
L
[N,C]
L [N,C]
L
[N,C]
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Table 5: SMARTS strings and chemical structure of oxygen group for AHR actives. 
 
  
SMARTS string Structual Feature
*~*(~*)=O
*~[#6](~*)-[#8]
c1c*o*1
A
A
A
O
A
A
HO
(a)
(a)
AO
(a)
A
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Table 6: SMARTS strings and chemical structure of oxygen substitute (nitrogen/ chlorine) for AHR 
actives. 
 
 
  
SMARTS string Structual Feature
[#6,#7]~1~[#6,#7]~[#6,#7]~2~[#6,#7]~[#6,#7]~[#6,#7]~[#6,#7]~[#6,#7]~2~[#6,#7]~1
[#7;a]~1~*~*~*~*~*~1
*n1ccnc1
Clc1ccc(cc1)-c1cc(Cl)c(Cl)c(Cl)c1
Clc1ccc(cc1Cl)-c1cc(Cl)c(Cl)c(Cl)c1
Clc1ccc(cc1Cl)-c1ccc(Cl)c(Cl)c1
Clc1cc(cc(Cl)c1Cl)-c1cc(Cl)c(Cl)c(Cl)c1
Cc1c(Cl)c(Cl)c(Cl)cc1-c1ccc(Cl)c(Cl)c1
L[C,N]
L
[C,N]
L
[C,N]
L
[C,N]
L [C,N]
L
[C,N]L
[C,N]
L
[C,N]L
[C,N]
N
(a)
A
A
A
A
A
A
N(a)
N
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
H
3C Cl
Cl
Cl
Cl
Cl
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FIGURE TITLES 
Figure 1: Ligand-protein interaction of 4NQA (PDB, 2014), showing potential hydrogen 
bond formation of oxygen groups on the ligand to key residues ARG278 and SER289 within 
the LXR binding domain 
Figure 2: Ligand-protein interaction of 2LBD (PDB, 2014), showing potential hydrogen bond 
formation between the ligand and the key residues LEU330 and ARG319 within the RAR 
binding pocket. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
